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Abstract: Cyanobacteria are among the first microorganisms to have inhabited the Earth. Throughout
the last few billion years, they have played a major role in shaping the Earth as the planet
we live in, and they continue to play a significant role in our everyday lives. Besides being
an essential source of atmospheric oxygen, marine cyanobacteria are prolific secondary metabolite
producers, often despite the exceptionally small genomes. Secondary metabolites produced by these
organisms are diverse and complex; these include compounds, such as pigments and fluorescent
dyes, as well as biologically-active compounds with a particular interest for the pharmaceutical
industry. Cyanobacteria are currently regarded as an important source of nutrients and biofuels
and form an integral part of novel innovative energy-efficient designs. Being autotrophic organisms,
cyanobacteria are well suited for large-scale biotechnological applications due to the low requirements
for organic nutrients. Recent advances in molecular biology techniques have considerably enhanced
the potential for industries to optimize the production of cyanobacteria secondary metabolites with
desired functions. This manuscript reviews the environmental role of marine cyanobacteria with
a particular focus on their secondary metabolites and discusses current and future developments
in both the production of desired cyanobacterial metabolites and their potential uses in future
innovative projects.
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1. Introduction
Cyanobacteria are photosynthetic prokaryotes. Despite the fact they are often referred to as
blue-green algae, they have no direct relation to higher algae. They are believed to be one of the
oldest organisms on Earth with fossil records dating back 3.5 billion years [1,2]. Cyanobacteria are
responsible for the Earth’s transition from a carbon dioxide-rich atmosphere to the present relatively
oxygen-rich atmosphere as a consequence of oxygenic photosynthesis [3]. Throughout their long
evolutionary history, cyanobacteria have diversified into a variety of species with various morphologies
and niche habitats.
Cyanobacteria present a diverse range of morph types, including unicellular, surface-attached,
filamentous colony- and mat-forming species. Several species form important symbiotic associations
with other micro- and macro-eukaryotes [4,5]. In keeping with the broad taxonomic diversity across
the phylum, cyanobacteria inhabit a diverse range of terrestrial and aquatic habitats, ranging from
deserts to freshwater and marine systems across a range of eutrophic and oligotrophic conditions. They
can also be found in extreme environments, such as Antarctic dry valleys, Arctic and thermophilic
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lakes [6,7], as well as in unlikely habitats for phototrophs, such as in the subsurface of calcareous rocks
(Gloeobacter violaceus) [8] and Lava Caves [9].
Throughout their evolutionary history, cyanobacteria have developed unique interactions with
other (micro- and macro-) organisms. Many of these interactions are based on a multitude of unique
and complex genetic pathways leading to the production of secondary metabolites [4,5]. Secondary
metabolites from cyanobacteria have been studied traditionally for their involvement in disease, e.g.,
microcystins and cylindrospermopsin, which trigger gastrointestinal illness, liver disease and kidney
damage, or for their medicinal properties, such as anticancer, antimicrobial and UV-protective activities.
The last decade has seen an increased interest in cyanobacterial research, resulting in an expansion of
the uses of cyanobacterial metabolites beyond the realms of public health and pharmaceutical industries
to include pigments, food and fuel production and other biotechnological applications [10,11].
Several recent publications have extensively reviewed the diversity and genetics of secondary
metabolite production in (marine) cyanobacteria [12–15]. Therefore, here, we summarize this
information and present insights into the current transition of research from traditional chemistry-based
screens to molecular engineering and synthetic biology. These advances will not only contribute to
basic knowledge, but will also further drive the use of cyanobacterial secondary metabolites in
novel applications.
2. Environmental Impact of Marine Cyanobacterial Secondary Metabolites
Some of the earliest research on cyanobacterial secondary metabolites derived from the study of
toxins produced by harmful algal blooms (HAB) and was mainly focused on freshwater species [16–18].
Toxin production by HAB can have dramatic health and economic impacts in lakes, rivers, estuarine
and coastal shores, resulting in the death of cattle and domestic animals, as well as shellfish poisoning,
leading to substantial financial loss to industries (Figure 1) [19].
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Figure  1.  Environmental  impact  of  photosynthetic microorganisms  in  aquatic  systems. Different 
classes of photosynthetic microorganisms are found in aquatic and marine environments where they 
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to human health,  livestock and  fish stocks. Positive  interactions are  indicated by arrows; negative 
interactions are indicated by closed circles on the ecological model. 
Figure 1. Environmental impact of photosynthetic microorganisms in aquatic systems. Different classes
of photosynthetic microorganisms are found in aquatic and marine environments where they form
the base of healthy food webs and participate in symbioses with other orga isms. However, shifting
environmental conditions can r sult in community dysbiosis, where the gr wth of opportunistic
species ca lead to harmful blooms and toxin producti n with negative consequenc s to human health,
livestock and fish tocks. Positive interacti ns re indicated by arro s; negative interactions are
indicated by closed circles o the ecological model.
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The structure, cellular target and bioactivity of HAB toxins are broad and include soluble
compounds of several types, such as neurotoxins, hepatoxins, cytotoxins, dermatoxins, in addition to
endotoxins, e.g., lipopolysaccharides (LPS). The best-studied examples of cyanobacterial toxins are the
neurotoxins; anatoxin-a/saxitoxin (Anabaena flos aquae) [20,21] and the potent hepatotoxin microcystins
(Microcystis sp.) [22]. However, while some of these toxin-producing freshwater cyanobacterial species
can expand into estuarine environments, it is interesting to note that toxin-producing unicellular species
rarely predominate in truly marine habitats [18]. In the marine environment, toxin production appears
limited to the filamentous colony-forming cyanobacteria, Oscillatoriales, Trichodesmium, Lyngbya
(reclassified as Moorea sp. [23]) and Nodularia, and the (phyto) planktonic dinoflagellates and diatoms.
Indeed, similar to freshwater cyanobacteria, these species form recurrent seasonal outbreaks leading to
toxic blooms affecting shellfish and finfish stocks with dramatic consequences for aquaculture and
human consumers [24]. The greater occurrence of HABs in estuarine and coastal waters has been
linked to increased eutrophication, in particular nitrogen and phosphorus loading due to runoff from
agricultural land. In recent times, greater public awareness and better agricultural management
practices in many developed countries have reduced the occurrence of nutrient-induced HABs.
However, ecosystem perturbations, such as localized heat waves, and habitat stress from human
activities, including aquaculture, urbanisation and shipping, are increasingly linked to recurrent
HABs [17,25], potentially as a result of the dysbiosis of microbial communities that form the base of
healthy marine ecosystems.
Several marine cyanobacteria produce toxins, although these genera appear less prevalent in
oceanic compared to coastal settings. Marine cyanobacterial blooms are more prominent in tropical
and sub-tropical regions, mainly in shallow reef areas. The main bloom-forming species include
Synechocystis, Oscillatoria, Lyngbya (Moorea [23]) and Symploca. Relative to their freshwater counterparts,
toxins produced by marine cyanobacteria are thought not to present a direct health risk, mainly due
to the fact that humans and domestic animals do not rely on seawater for drinking. However, they
can lead to secondary health risks through bioaccumulation or poisoning of fishes and other seafood.
To date, the major human health risk of marine cyanobacteria has been associated with members of the
genera Oscillatoriales, Moorea and Trichodesmium. For example, Lyngbya majuscula (Moorea producens)
is a prolific producer of diverse secondary metabolite compounds, including lyngbyatoxins and
majusculamides. These marine cyanobacterial toxins have a broad range of biological activities,
including dermatotoxic, cytotoxic, neurotoxic and tumorigenic activities [12,18].
Specific environmental conditions, especially enriched nutrient conditions, such as phosphorus
and iron, promote the growth and formation of mats and coastal blooms attributed to
Lyngbya/Moorea [26]. During these times, the overgrowth of the cyanobacteria and toxin production
have become the cause for the closure of beaches partly due to the presence of skin irritant dermatoxin
known to cause “swimmers’ itch” [27]. These outbreak events lead to reduced public confidence in
seafood and equally damage the tourism industry. Estimates drawn in the U.S. state that harmful
algal blooms (HABs) were costing approximately US$100 million per year to the U.S. economy in lost
fishery production and stocks, human illness and lost tourism revenue [28], totalling upwards of US$1
billion during the past decades [29,30]. In Australia, the negative impact of cyanobacterial HABs was
estimated to cost $180–240 million per year [31,32], with some blooms of photosynthetic microbes
hypothesized to dramatically affect local businesses. Indeed, blooms of Nodularia and specifically
N. spumigena, a brackish heterocystous genus producing hepatotoxin nodularin, have repeatedly
caused issues around Australia and appear to be gradually expanding their biogeography [33,34]. In
September 2008, one such bloom at a brackish lake in Queensland forced the closure for recreational
access of a cable ski operation for a duration of three months at an estimated cost of AUD$300,000 [34].
Interestingly, the genome sequencing of L. majuscula (Moorea producens) suggested that it uses
precursors from other surrounding bacteria to synthesise a proportion of its toxins [35–37]. Therefore,
Moorea’s toxicity could be the result of a network association with metabolic exchanges between the
various individuals in the microbial community. Thus, in order to mitigate the negative impacts
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of marine cyanobacterial toxins, it is important study these organisms within the appropriate
ecological context.
3. Ecological Role of Marine Cyanobacterial Secondary Metabolites
Marine cyanobacteria can be found in various environmental niches, both as pelagic free-living
forms and in the benthos, either forming mats on surfaces, or as symbionts of eukaryotes, such as
sponges, ascidians or kelps. The benthic or host-associated forms of marine cyanobacteria appear
to be a richer source of complex bioactive secondary metabolites, likely due to the character of this
ecological niche, which facilitates a highly competitive and relatively nutrient-rich environment
provided by the host [38,39]. Notably, multiple compounds, which were originally thought to be
produced by higher organisms, such as sponges and ascidians, such as dolastatin and analogues
(sea hare) leucamide A (sponge) and westiellamide (tunicate), are now shown to be synthesized by
an associated cyanobacterium [12,37,40,41]. These marine cyanobacteria live in a complex ecosystem
defined by close associations and intense competition from other members of the community and
a higher frequency of encounters with numerous predators, including grazers and phage. Many of the
metabolites they produce are thought to play an important part of defence mechanisms to attempt to
gain the upper hand and thrive within their niche of choice.
Some marine cyanobacteria produce small molecules with structural similarity to compounds
involved in bacterial quorum sensing, such as acyl-homoserine lactones [14]. These molecules act
as inhibitors of bacterial quorum sensing; however, their mode of action is unclear, as, despite their
structural similarity to known acyl-homoserine lactones, the cyanobacterial compounds were not
shown to act as direct competitive inhibitors [42]. For example, Lyngbya (consisting probably of the
renamed Moorea sp.) is known to proliferate in dense microbial mats and to produce several interfering
metabolites, such as malyngamide, malyngolide and lyngbyoic acid [43–46]. In this habitat, the
production of quorum sensing-interfering compounds may provide an advantage by interfering with
regulatory networks of competitors [36]. Many of these compounds from marine organisms, including
not only cyanobacteria, but also algae, fungi, tunicates and sponges (many secondary metabolites of
which could be the result of cyanobacterial symbionts), have attracted commercial interest as they could
prove useful in preventing marine biofouling through bacterial quorum sensing inhibition, as was
shown for Microlins A and B from L. majuscula (now Moorea sp.) [47]. Planktonic marine cyanobacteria
have also been reported to produce allelopathic compounds to gain advantage in some habitats.
For example, Synechococcus CC9605, a coastal-dwelling cyanobacterium, has been shown to produce
microcin C-like metabolites that inhibit the growth of other cyanobacteria strains [48], and marine
Cyanobium strains produce bioactive compounds against a range of other marine organisms [49].
Due to their abundance and role as the base of the many aquatic food chains, cyanobacteria
are constantly consumed by larger planktonic microbes, filter feeders and grazers. Hence, it is not
surprising that cyanobacteria have developed effective chemical deterrents [36]. These molecules,
which act as herbivore deterrents, are produced by benthic marine cyanobacteria and are excreted
or exported to alter cell surface properties that lower their palatability to predators. Many have no
demonstrated toxicity, but may act as repellents, leading to starvation of the grazer by removing their
only food source, as these grazers will not feed on the cyanobacterial mat. For example, production of
ypaoamide (Figure 2) by the assemblage of Schizothrix calcicola and L. majuscula acts a as deterrent to
macrograzers, such as rabbitfish and sea urchins [50], and other yet unknown chemical deterrents from
L. majuscula act against various grazers, such as sea urchins, crabs and other amphipods [51]. Despite
these efficient deterrent mechanism, some mesograzers still feed on toxic cyanobacteria and have
succeeded to adapt cyanobacterial defence systems for their own use. Indeed, sea hares accumulate
large amounts of metabolites within their tissues, which are hypothesized to be derived from their
cyanobacterial diet [52].
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Figure 2. Examples of various secondary metabolites and pigments structures produced by
marine cyanobacteria.
A different approach to surviving competition and predation employed by cyanobacteria is to
establish a stable symbiosis with a higher organism, which provides shelter in return for nutrients
and other compounds that benefit the host. For example, marine cyanobacteria exude up to 30%
of their photosynthates, carbon-rich metabolites, into their surrounding environment [53]. This is
hypothesized to be an important factor for their co-existence in symbiosis, e.g., in sponges, as this would
alleviate the need of the host to rely solely on heterotrophy [54,55]. Multiple cyanobacteria produce
auxin-like compounds, such as the phytohormone indole-3-acetic acid (IAA), which is hypothesized
to be important in the establishment of cyanobacterial associations with photosynthetic eukaryotes
(Figure 2). In support of this, Sergeeva et al. [56] found that 83% of the symbiotic isolates tested positive
for the production of auxin-like compounds compared to 38% of the free-living ones. Moreover, IAA
produced by Nostoc was recently sho n to be necessary for it to colonize plant roots and additionally
promoted plant growth [57,58].
Due to their obligate exposure to sunlight, cyanobacteria ave developed mechanisms to protect
their cellular components from the more harmful wavelengths of th light spectrum. I deed, UV
radiation induces amage a a number of cellular argets where damage can disrupt cell functioning.
Some species produce photo-protective metabolites that offer a strong screen against ultra violet
radiation, posses antioxid nt properti s [59,60] and can b stored inside r outside of the c ll. Due to
their UV-ab orbing capacity, they e also referr d to as cyanobacterial uns reen [36]. Carotenoids,
represented by a large and diverse set of c mpounds, including beta-c otene, zeaxanthin, ec inenone
and myx l pentosides (Figure 2) [61], are argely recognized as the most photo-protective of the
intracellular mol cules in cyanobacteria. Marine cyanoba teria also accumulate different variants of
mycosporines and mycospori e-like amino acids (MAAs) that protect the cells mainly against UV-A
radiation and, to a lesser extent, against UV-B radiation. Inter stingly, the protective properties of
MAAs c n be transferred to higher trophic levels in the food chain, e.g., fishes were shown to contain
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various types of MAAs in their mucus, which may provide protection against UV radiation [62].
In addition to its UV protective role, MAAs can be modified by some species of sea hares and used
in high concentrations as a chemical deterrent against competing species [63]. Some cyanobacteria
also produce photo-protective molecules that are localized in the extracellular sheath, e.g., the UV-A
protectant scytonemin (Figure 2). Scytonemin was also shown to protect the cell against UV-C and is
believed to be an early form of photo-protectant [64].
Marine cyanobacteria are prolific producers of vitamin B complex and vitamin E [65]. They
synthesize vitamin B12 for their internal metabolism and release excess through excretion in their
surrounding environment. It was shown that nitrogen-fixing cyanobacteria excrete more vitamin B12,
an N-rich molecule (Figure 2), than non-nitrogen-fixers [66]. Cyanobacteria have been hypothesized
to be a major source of vitamin B12 that supports the growth of larger auxotrophic eukaryotic
phytoplankton [66,67]. They may also support the growth of a range of auxotrophic bacteria and,
hence, further sustain the diversity and health of the whole ecosystem (e.g., B12 auxotrophic SAR 11
bacteria) [68,69].
4. Biotechnological Applications for Marine Cyanobacterial Secondary Metabolites
4.1. Inhibitory Bioactive Metabolites
In addition to their ecological role, bioactive metabolites produced by marine cyanobacteria
present valuable applications for agriculture, health and biofouling, but in particular, for the
pharmaceutical industry, with potential for therapeutic applications [70].
Many cyanobacterial bioactive secondary metabolites are produced via non-ribosomal peptide
synthase (NRPS) and polyketide synthase (PKS) biosynthetic pathways [15,71] compared to only a few
derived from ribosomal proteins. Synthesized molecules include alkaloids, amides, fatty acids, indoles
and peptides/depsipeptides [13,72]. This large spectrum of complex molecules presents great potential
for therapeutic and biotechnological applications [13,73].
Due to the diminishing impact of classical antibiotics and the urgent need for new therapeutic
drugs, there is a push for large programmes to screen secondary metabolites from marine sources for
bioactive compounds [12,39,74]. Genes encoding novel bacteriocins [75] and antimicrobials, such as
lantipeptides, have been discovered in numerous marine cyanobacterial genomes, e.g., Prochlorococcus
MIT9313 [76], and are opening new avenues for research to combat multidrug-resistant microorganisms.
The biocidal activity of cyanobacterial secondary metabolites towards biofilm-forming bacteria has
also been proven to be of use for potential anti-biofouling applications, i.e., deterrent of the fouling
benthic diatom Nitzschia pusilla by Cyanobacteria from Scytonema hofmanni [77].
Numerous promising compounds have been identified with strong anti-proliferative activities
and potent anti-cancer/tumour properties (e.g., apratoxins, dolastatin 10 (Figure 2) [78–81], as
well as anti-viral (e.g., several anti-HIV compounds, as summarized in [10]), anti-malarial (e.g.,
gallinamide A) [82], anti-trypanosomal and anti-leishmanial activities (viridamide A, Oscillatoria
nigroviridis [83]; dragonamide E [84]), in addition to anti-inflammatory and neurotoxic activities.
Some effective bioactive compounds have been shown to act as modulators of important metabolic
enzymes. Several of these target or modulate, in a positive or negative manner, the activity of kinases
or proteases associated with the development of tumours. While activators of protein kinase C,
leading to tumour promotion, were isolated from the prolific metabolite producer L. majuscula, e.g.,
indole alkaloids, such as lyngbyatoxins [85]. Various other compounds of cyanobacterial origin and
acting as enzyme inhibitors have been discovered in recent years. These include (serine-) protease
inhibitors, lyngbyastatins [86,87], symplocamide, a chymotrypsin inhibitor with a high level of toxicity
towards cancer cells (Figure 2) [88,89], and cyclodepsipeptides with elastase inhibitory activity, such
as tiglicamides [90]. Some compounds have been shown to be highly specific histone deacetylases
(HDAC) inhibitors, also affecting non-histone protein substrates and thus acting on downstream
cellular pathways; altogether, they offer promising new disease treatments [91]. For example, two
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metabolites isolated from Symploca sp. were shown to have high activity towards HDAC: the potent
and selective anti-proliferative santacruzamate A (Figure 2) [92] and the cyclic dipepsipeptide largazole
specific to class I HDAC (Figure 2) [93–96].
Previous authors have reviewed the diverse molecules produced by both marine and freshwater
cyanobacteria along with their structures and modes of action [12,42,73,97]. A large number
of the compounds produced from either free-living or in symbiotic cyanobacteria are in clinical
trials [72,73,79]. While a number of the trials (phase I and/or II) have been terminated due to strong
host toxicity, e.g., the semi-synthetic cryptophycin 52, or cemadotin (LU103793), a synthetic analogue
of dolastin 15 causing hypertension and cardiotoxicity [73], several of these natural products present
promising leads for combinatorial chemistry and targeted modification techniques to develop efficient
drugs with lower levels of toxicity, e.g., santacruzamate A and tasidotin (ILX-651, synthetic derivative
of dolastatin 15) [73].
4.2. Nutritional Supplements, Pigments and Chromophores
As photosynthetic microorganisms, cyanobacteria harvest light as their energy source through
a wide variety of photosynthetic antennae that are rich in pigments and chromophores. Several
chromophores (e.g., tetrapyrroles) from the light-harvesting complexes (e.g., phycobilins and
chlorophylls; Figure 2) have been reported to have beneficial health effects, e.g., providing
micronutrients and macronutrients, aiding in digestion, etc. There is a blooming market for the
use of cyanobacteria as beneficial human food/health supplements, and they are now being widely
utilized in the nutraceutical industry. Among the most widely-used species is the halotolerant Spirulina
(Arthrospira platensis and Arthrospira maxima). Spirulina cells have a high nutritional value and high
digestibility, due to their richness in various nutrients and high protein content. They also present
additional health benefits as a source of antioxidants, coenzymes and vitamins [59].
Marine phytoplankton, including cyanobacteria, are a rich source of pigments and carotenoids [61].
These have been historically used as colouring agents and colour enhancers and are now back to
prominence due to health concerns over the use of chemical colouring agents.
Alongside their application as food for human consumption, microalgae are used as a feedstock
in aquaculture and as soil additives for agriculture [98]. There is a drive to reduce the use of chemical
fertilizers in agricultural soils due to their negative ecological impact. Seaweed has been traditionally
used to improve soil quality in various regions of the world [99,100]. Cyanobacteria cells are rich in
nitrogen, mainly from their N-rich photosystem antennae, with several species also fixing atmospheric
dinitrogen; therefore, they are an ideal soil supplement already proven beneficial in the growth of
rice [101]. Some cyanobacterial strains have the additional benefits of producing metabolites with
herbicidal properties [102]. The production of compounds using cyanobacterial cells creates a large
amount of biomass as a by-product that can be recycled as soil additives for agricultural purposes.
Cyanobacterial chromophores have equally found technical applications as molecular tools. These
compounds, e.g., phycoerythrin, are routinely used as conjugates of molecules (antibodies) allowing
qualitative and quantitative visualization from their desirable fluorescence properties with high signal
intensity [103].
4.3. Biofuels, Industrial Processes and Engineering
Due to the depletion of Earth’s finite resources and the implications of climate change, there
is currently a strong incentive to develop renewable alternatives to fossil fuels. Biofuels have been
considered as a possible avenue to replace at least a proportion of the total fossil fuel consumption.
Though the initial push focussed on biofuels produced from cellulosic waste, economic and technical
production challenges with this approach have led to the emergence of algae-based biofuels (either
from eukaryotic microalgae or cyanobacteria) as a more sustainable alternative [104]. The U.S. congress
established a mandate, the Renewal Fuel Standard (RFS), requiring a proportion of the national fuel
supply to be composed of alternative fuel sources, such as biofuel. The mandate required an increase
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of cellulosic biofuels, which is currently not being met. There are now increased discussions about the
place of algae biofuel within the RFS [105,106]. Indeed, funding in algae R&D from the U.S. Department
of Energy is currently on an increasing trajectory and has reached a cumulative $236 million as of
December 2010. Recently (July 2015), the U.S. Department of Energy announced an $18 million USD
grant on six new algal biofuel projects. Europe has equally seen a large push in algae R&D, in biofuel
and other algal-derived products, to meet the European Union’s environmental regulations and in
a conscious effort to reduce the global carbon footprint.
Many of the lipid-based biofuels are based on eukaryotic microalgae; however, marine
cyanobacteria present further developmental advantages for optimizing industrial production, partly
due to their smaller genome size, the fact that some of them are more genetically amenable and
halotolerant [107], which provides the advantage of utilising abundant seawater resources for growth,
rather than freshwater supplies, which are limited in many regions of the world. Several companies
have made large investments in R&D over the past few years using modified brackish/marine
cyanobacteria and are strengthening their aims towards commercial viability of their production
process. Algenol (Fort Myers, FL, USA), founded in 2006, is using a modified cyanobacterium
growing in saltwater (advantageous, as saltwater is a far more abundant and low cost resource
than freshwater in many regions). The company produces various biofuels (ethanol, biodiesel,
renewable gasoline and jet fuel), as well as high value chemicals [108]. Another successful, but
secretive company and direct competitor of Algenol, is Joule Unlimited (Bedford, MA, USA) [109].
The Massachusetts-based company Joule Unlimited has been granted a U.S. patent (US 9,034,629B2)
on 19 May 2015, covering their production process and genetically-modified cyanobacteria. The
production from the brackish/marine cyanobacteria is not reliant on biomass production, but the
compound is secreted into the culture medium. Furthermore, to suggest the commercial strength of
the process, Joule Unlimited has established a partnership with Audi AG (September 2012) [110] and
more recently (November 2015) merged with the biofuel maker company Red Rock Biofuels LLC (Fort
Collins, CO, USA) [111]. Möllers et al. [112] also demonstrated that cyanobacterial biomass could be
used as an efficient feedstock for bioethanol production by yeast fermentation. This study highlighted
the high efficiency of transforming light energy to biomass, while also pointing out that cyanobacteria
produce simplified cell walls and glycogen as the main storage polymer, which is far easier to mobilise
than starch, the main storage polymer for eukaryotic algae.
Furthermore, some marine cyanobacteria, e.g., Cyanothece 51142, have been reported to produce
high rates of hydrogen that can be harnessed as a renewable fuel [113,114]. Hydrogen is formed
as a by-product of nitrogen fixation and is an attractive form of carbon-neutral renewable energy.
The relatively high rates of hydrogen production found in nitrogen-fixing marine cyanobacterial
provide promising avenues for further industrial applications.
Cyanobacteria and their metabolites are being exploited for use in wastewater treatment,
bioremediation and biofouling. They have been reported to be an important part of the consortium for
the oxidation of oil and complex organic compounds. However, it was shown that cyanobacteria were
not directly involved in the process, but facilitated this process carried out by heterotrophic bacteria
within the system [115]. Cyanobacteria were also shown to be prolific producers of exopolysaccharides
(EPS), which have promising applications as biosurfactants and bioemulsifiers [116,117], e.g., emulcyan
from the cyanobacterium Phormidium J1 [118]. EPS can equally be used for the absorption of heavy
metals [99]. Biocide activities are of great interest for biofouling when applied directly to or mixed in
paints for (submerged) surfaces [77].
The production of cyanobacterial biomass is inherently linked to CO2 sequestration; therefore,
their use for industrial production has the potential to reduce the industrial carbon footprint. Some
cyanobacterial strains assimilate and accumulate carbon into polymers, poly-hydroxyalkanoates
(PHA) [10], which has attracted the attention of industrial companies as a way to potentially achieve
carbon-neutral production of plastics in a much more cost-effective fashion compared to “traditional”
plastics. These bioplastics also present a better biodegradability. Despite the efficient CO2 fixation, the
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production of biomass, in particular biofuels, requires additional nutrients, such as N and P. To alleviate
the need for the input of extra nutrients, several applications have been established successfully using
wastewater as a nutrient source [119].
4.4. Frontier Technologies
Photosynthetic organisms have the advantage of using light as an energy source and atmospheric
CO2 as a carbon source. However, for both plants and the most commonly-used photosynthetic
microbes, the demands for large spaces and copious amounts of freshwater pose challenges for
keeping production costs low. The use of cyanobacteria growing in saltwater, with potential recycling
of wastewater and use of non-arable land, would reduce both costs and environmental impacts [120].
Many isolates of marine cyanobacteria also display small streamlined genomes (<3.0 Mb) [121] and
simplified cell-walls and storage polymers [112] relative to their eukaryote counterparts, which make
them promising platforms for genetic and metabolic engineering to optimize the production of biomass,
as well as yield and the recovery of secondary metabolites.
4.4.1. Food Supplements
The production of high cyanobacterial biomass is a necessity for a wide range of applications,
from small-scale setups to large-scale processes and, eventually, for commercialization. Cyanobacterial
biomass production for food supplements continues to be a booming market, with continued
expected growth [122–124]. One of the major cyanobacterial species utilised is the halotolerant
Arthrospira platensis that can grow under freshwater, brackish and saltwater conditions [110].
Companies have based their business on the sale of Spirulina, grown in brackish waters, as a nutritional
supplement for human consumption (protein, chlorophyll, vitamins and minerals) [125,126], e.g.,
Nutrex Hawaii (Cyanotech corporation, Kailua-Kona, HI, USA). The high nutritional value of
cyanobacteria makes them attractive for the future of food. Several aeronautic agencies (NASA,
National Aeronautics and Space Administration; JAXA, Japan Aerospace Exploration Agency; ESA,
European Space Agency) are considering the use of algae to supplement astronauts’ diets. Furthermore,
they have also launched research programs on the application of algae, such as Spirulina, as primary
food for long-duration space travel or deep space missions. Indeed, in such missions, algae could
be involved in replenishing oxygen, as well as providing a renewable source of food and fuel, while
recycling waste [127].
4.4.2. High Value Products
A promising pathway is the use of cyanobacteria by industries to produce cell biomass for
the production of high value products. Hays and Ducat [128] proposed that cyanobacteria were
ideal alternatives to plants for carbohydrate feedstocks. Proterro, Inc. (New York, NY, USA) uses
a patented technology platform, modifying cyanobacteria that utilize waste CO2 to offer industrial- and
food-grade sugars and a nutritional range of products, such as amino acids, nutrients and vitamins.
4.4.3. Biofuels
Further developments linked to biomass production relate to the production of biofuels [129].
As previously discussed, the global push for cleaner energy and reduced carbon emissions has
stimulated large-scale developments in order to decrease costs and streamline production. Several
companies are investing in extensive R&D in this field. For example, Origin Clear Inc. (Los Angeles,
CA, USA) [130] patented innovative processes for the separation of oil produced by eukaryotic
microalgae, and they have refined a process for the live extraction of oil from microalgae (patent US
20120040428 A1). This technology allows for continuous oil production from high biomass compared
to the batch-type production where the biomass is fully harvested before oil extraction.
In March 2016, the Helioculture process from Joule Unlimited, based on cyanobacteria, obtained
approval from the U.S. Environmental Protection Agency (EPA) as a pathway for the generation of
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advanced biofuel RINs (D- code 5) under the RFS program [131]. It was calculated that this process
achieves more than 85% lifecycle greenhouse gas reduction from the gasoline baseline. In addition to
the secretion of bioethanol from the producing cyanobacterial cells, Joule Unlimited further processes
its cyanobacterial biomass to produce an algal oil product. From the company’s successes, Joule
Unlimited aims at constructing its first commercial facility by 2017, with a forecasted production price
competitive to $50 per oil barrel.
4.4.4. Energy-Efficient Green Buildings
Due to the move towards renewable energies and the reduction in carbon footprint, innovative
concepts have emerged for the application of algae farms in setups other than traditional industrial
productions. The idea of scalable algae farms incorporated into the landscape, both inside and outside
of cities, has been proposed [132]. One of the most successful and sought after applications is the
new concept of algae architecture as part of energy-efficient “green” buildings and landscape designs
(Figure 3). For example, to integrate algae into the fabric of buildings for recycling CO2 and wastewater,
thus providing a carbon-neutral workplace that manages its own wastes and transforms wastes into
high value products, such as biofuels [133,134]. This concept has already been successfully applied,
for example in the Bio Intelligent Quotient (BIQ) house in Hamburg (Figure 3A) constructed and
finished in 2013 [135]. The BIQ house is surrounded by facades of microalgae cultivation panels linked
and integrated into the functioning of the building to reduce its environmental carbon footprint. The
heat generated from the algae growth is recycled through thermal exchangers and used for heating,
as well as producing biomass for use in biodiesel [135]. Other examples of integrated algae design
can be found in a retrofitted system on the La Defense building in Paris, France, aimed to reduce the
environmental footprint of the building merging concepts of algae farms, algae biofuel and wastewater
treatment [136], and in Italy, where the company Algaetecture presented a prototype urban algae
canopy (Figure 3B) [137]. Cesare Griffa Architecture lab [138] designed several projects based on
microalgae systems, e.g., Bioskin and the Lillies series (part of the prototype urban algae canopy;
Figure 3B), that can be adapted to and used with various microalgae and, in particular, Spirulina sp.
Several eco-architects have further worked on integrating living plant/algae within architecture
prototypes exploiting the production of microalgal biomass into the functioning of the building design
(Figure 3C).
4.4.5. Genetics and Synthetic Biology
The evolution of cyanobacterial strains for growth at high densities and for enhanced production
levels of desired metabolites would be essential in the large-scale industrial applications with
an overarching aim of achieving optimal production at reduced costs [139]. The past decade has
witnessed a boom in the sequencing of the genetic material of microorganisms and a revolution in omics
technologies. The emphasis has moved from the simple analysis of one gene in one system to global
analyses of biological networks and synthetic redesign of biological systems. The interdisciplinary
field of synthetic biology provides interesting options for future biotechnological applications.
The development of -omics technologies and the large amount of sequencing data being generated
from previously untapped habitats and microbial communities, provide a great resource for potential
new targets/biosynthetic pathways [37,140,141]. Genetic engineering for the synthesis of new
molecules is already successfully conducted in Escherichia coli. For example, patellamide, originally
identified from a cyanobacterial symbiont of ascidians, was successfully produced by recombinant
Escherichia coli [142]. Cyanobacteria have already been modified to produce metabolites through
synthetic pathways, such as isopropanol [143]. Using identified biosynthetic genes (PKS/NRPKS)
in order to engineer complex molecules with specific bioactivities is a widespread approach in
combinatorial chemistry and/or synthetic biology [144,145]. These developments open infinite
possibilities in the development and assessment of lead compounds in a widening range of applications,
including in the development of pharmaceuticals.
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Figure 3. (A) Bio Intelli t ( I ) The Clever Tr efrog—The Algaehouse, housing-project
at the I rg. Idea, concept and authorship: SPLITT WERK, Label for Fine Arts, Graz;
Arup GmbH, Berlin; B+G I genieure Bollinger und Grohmann GmbH, Frankfurt; Immosolar GmbH,
Hamburg. Photo by S I 3. (B) Urban Algae Façade pr totype by Cesare Griffa and
Carlo Ratti Associati; prototy i g tea : atteo Amela, Federico Borello, Marco Caprani; technical
support by Environ ent Park Spa, Fotosintetica icrobiologica Srl; lighting by iGuzzini. Photos
by Filippo Ferraris. 2014 Salone del obile, ilan, Italy. (C1) Process Zero Exterior: the eight-story,
1960s-era building is among the 362 million square feet of office space the GSA must retrofit to
reduce greenhouse gases by 30 percent before the 2020 deadline. Image credit: HOK/Vanderweil.
(C2) Process Zero Exterior Facade Detail: algae, housed in glass tubes covering the building’s exterior,
filters wastewater, consumes carbon dioxide from the nearby highway and uses photosynthesis
to produce energy. Image credit: HOK/Vanderweil. (C3) Concept image created for the Perth
Photobioreactor Design and copyright to Tom Wiscombe architecture. (C4) The FMSA Tower concept
project, a self-sustainable skyscraper. Design and copyright to Dave Edwards. All photographs and
artwork reproduced with permission of the authors.
5. Conclusions
Since much of the attention in relation to metabolite production has been historically focused on
their freshwater counterparts, marine cyanobacteria present a relatively untapped resource in terms of
evolutionary diversity and industrial potential. They are prolific producers of diverse and complex
secondary metabolites with potential applications in health, biofuels and bioengineering. They have
mi imal genomes a d low cellular resource requirements, which make them well suited for genetic
and met olic e gineering. In light of demands on natural resources, including freshwater, nutrients
and arable land, marine cy nobacteria offer an important adv n age ve their freshwater counterparts
for industrial-scale processes, .e., they are adapted growing in brackish and salt water. Coupled
with their ability to convert sunlight to energy, th se o ganisms ave the capacity to serve as low
cost, adaptable cellular factories capable of producing high-value products and biofuels with low
environmental impact.
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Cyanobacteria and, particularly, the marine dwellers have become increasingly integral parts of
future innovative projects, from aeronautic programmes to concept projects in sustainable architecture.
The incorporation of algae into novel architectural designs has the potential to improve waste recycling,
climate control and reduce the carbon footprint of commercial buildings. Much is still unknown about
marine cyanobacterial metabolites; however, there is a great deal of progress being made using recent
advances in molecular techniques, including large-scale environmental genome sequencing projects,
metabolic modelling and synthetic biology approaches. Expanding the potential biotechnological
benefits of marine cyanobacteria will benefit from collaborations across the fields of ecology, genomics,
chemistry, health research and engineering and will result in the development of new technologies,
including extending the range of cyanobacterial metabolites beyond traditional uses, optimizing
biofuel production by using non-arable land and abundant saline water resources and contributing to
the ecological buildings of the future.
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